The Impact of Genexpert MTB/RIF Technology on the Minimization of Tuberculosis: A Review of Literature

Abstract

The molecular revolution in tuberculosis (TB) diagnosis has ushered in a new era of patient treatment that is quicker, more accurate, and clinically appropriate. In cases where treatment resistance is suspected or if tuberculosis (TB) is present, the most cutting-edge molecular diagnostic tool available is the Xpert test developed by Cepheid in Sunnyvale, California. In December 2010, it was swiftly recognized as the main technique for TB diagnosis by the World Health Organization. This comprehensive review provides an in-depth understanding of TB and GeneXpert technology and its impact on the minimization of TB. The leading infectious disease killer in 2019 was tuberculosis (TB). Worldwide, tuberculosis (TB) killed an estimated 1.2 million people in 2019, with an additional 208,000 lost to the disease among HIV-positive individuals. almost the world, the sickness affected almost 10.0 million people. Of all tuberculosis cases, 88% were in adults, while 12% were in children less than 15 years old. The 2019 tuberculosis case rates were lower in the East Mediterranean (8.2%), the Americas (2.9%), and Europe (2.5%), compared to the World Health Organization (WHO) zones of South-East Asia (44%), Africa (25%), and the Western Pacific (18%). This study will provide an in-depth understanding of GeneXpert technology and its impact on the healthcare system.